Results 301 to 310 of about 1,905,672 (358)

Biochemical Recurrence after Radical Prostatectomy

DeckerMed Urology, 2018
After receiving local treatment, many patients will develop a biochemical recurrence (BCR) in the absence of detectable distant disease (cM0) and comprise a significant proportion (20.1%) of prostate cancer disease states. The natural history of patients with BCR ranges from those with indolent, nonprogressive, slow prostate-specific antigen (PSA)-only
Brian Chapin, Scott Delacroix, Dunia Khaled   +2 more
openaire   +1 more source

Management Options for Biochemically Recurrent Prostate Cancer

Current Treatment Options in Oncology, 2017
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging.
Farhad, Fakhrejahani, Ravi A, Madan, William L, Dahut   +2 more
openaire   +2 more sources

Characterization of Biochemical Recurrence after Radical Prostatectomy

Urologia Internationalis, 2006
<i>Background:</i> This study sought to characterize the variables that predict postoperative prostate-specific antigen doubling time (PSADT) and biochemical recurrence time (RT) in patients who have failed radical prostatectomy (RP).
Joseph, Molitierno, Aubrey, Evans, James L, Mohler, Eric, Wallen, Dominic, Moore, Raj S, Pruthi   +5 more
openaire   +2 more sources

Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.

European Urology Oncology, 2020
Biochemical recurrence of prostate cancer (PCa) after curative radiotherapy is defined as a prostate-specific antigen (PSA) rise of ≥2 ng/ml above the nadir ("Phoenix criteria", 2005).
B. Jansen, P. V. van Leeuwen, M. Wondergem, Tim M. van der Sluis, J. Nieuwenhuijzen, R. Knol, R. V. van Moorselaar, H. G. van der Poel, D. Oprea-Lager, A. Vis   +9 more
semanticscholar   +1 more source

Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*

Current Opinion in Urology, 2005
Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising prostate-specific antigen levels.
John F, Ward, Judd W, Moul
openaire   +2 more sources

Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer*

Current Opinion in Urology, 2005
The introduction of prostate-specific antigen into clinical practice heralded a dramatic shift in the epidemiology of prostate cancer. The diagnosis and treatment of lower stage disease in younger men with fewer competing co-morbidities has resulted in a longer period of post-treatment cancer surveillance and the potential for disease recurrence.
John F, Ward, Judd W, Moul
openaire   +2 more sources

Biochemical Recurrence after Localized Treatment

Urologic Clinics of North America, 2006
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it ...
openaire   +2 more sources

Immunotherapy for biochemically recurrent prostate cancer.

Journal of Clinical Oncology, 2018
215 Background: Annually about 30-50,000 men are diagnosed with biochemically recurrent prostate cancer (BCRpc), defined by a rising PSA after radical prostatectomy (RP) or definitive radiation therapy (RT) with negative conventional imaging (CT and bone scan). Standard treatments include salvage therapies, androgen deprivation or surveillance.
Ravi Amrit Madan, Fatima Karzai, Marijo Bilusic, Julius Strauss, Susan F. Slovin, Lauren Christine Harshman, Marc Robert Theoret, Philip M. Arlen, Myrna Rauckhorst, Anna Couvillon, Amy Hankin, Monique Williams, Philip W. Kantoff, William L. Dahut, Jeffrey Schlom, James L. Gulley   +15 more
openaire   +1 more source

PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.

Radiology, 2020
Background National guidelines endorse fluorine 18 (18F) fluciclovine PET/CT for the detection of prostate cancer (PCa) in men with biochemically recurrent PCa.
N. Tan, Udochukwu E. Oyoyo, Niusha Bavadian, Nicholas Ferguson, Anudeep Mukkamala, J. Calais, M. Davenport   +6 more
semanticscholar   +1 more source

External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort.

European Urology, 2019
The impact of biochemical recurrence (BCR) after radical treatment of prostate cancer on oncological outcomes remains unclear. A new European Association of Urology BCR risk stratification (low and high risk) has been proposed.
D. Tilki, F. Preisser, M. Graefen, H. Huland, R. Pompe   +4 more
semanticscholar   +1 more source